Triple therapy with boceprevir or telaprevir for prior HCV non-responders

Best Practice and Research: Clinical Gastroenterology

Volumn 26, Issue 4, 2012, Pages 455-462

  Asselah, Tarik ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

NS5A inhibitors; Pegylated interferon; Polymerase inhibitors; Protease inhibitors; Ribavirin

Indexed keywords

ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; ERYTHROPOIETIN; PEGINTERFERON; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PLACEBO; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

AMINO ACID SUBSTITUTION; ANEMIA; ANTIVIRAL RESISTANCE; DRUG ERUPTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAPID VIROLOGIC RESPONSE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84870414990     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2012.09.003     Document Type: Article

References (18)

1. EASL Clinical practice guidelines: management of hepatitis C virus infection J Hepatol 55 2 2011 245 264
2. T. Asselah, and P. Marcellin Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow Liver Int 2012 88 102
3. S. Maylin, M. Martinot, and R. Moucari Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C Gastroenterology 135 3 2008 821 829
4. M. Martinot-Peignoux, C. Stern, and S. Maylin Twelve weeks posttreatment is as relevant as 24 weeks to determine the sustained virological response in patients with hepatitis C virus Hepatology 51 4 2010 1122 1126
5. T. Asselah, I. Bieche, and S. Narguet Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C Gut 57 2008 516 524
6. M. Martinot-Peignoux, S. Maylin, and R. Moucari Virologic response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin Anti-vir Ther 14 2009 501 511
7. B.R. Bacon, S.C. Gordon, and E. Lawitz Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 13 2011 1207 1217
8. S. Zeuzem, P. Andreone, and S. Pol Telaprevir for retreatment of HCV infection N Engl J Med 25 2011 2417 2428
9. E. Estrabaud, M. Vidaud, P. Marcellin, and T. Asselah Genomics and HCV infection: progression of fibrosis and treatment response J Hepatol 57 5 2012 1110 1125
10. T.L. Kieffer, S. De Meyer, and D.J. Bartels Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment experienced patients receiving telaprevir-based therapy in clinical trials PLoS One 7 4 2012 e34372
11. S. Zeuzem, R.J. Barnard, and J.A. Howe Boceprevir resistance-associated variants (RAVS) are observed more frequently in HCV (GT1)-infected patients with poor response to peginterferon alfa-2B/ribarivin J Hepatol 2011 S4 S5
12. D. Ge, J. Fellay, and A.J. Thompson Genetic variation in IL-28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 391 401
13. T. Asselah Genetic polymorphism and response to treatment in chronic hepatitis C: the future of personalized medicine J Hepatol 52 2010 452 454
14. E. Gane, S. Roberts, and C. Stedman Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 376 2010 1467 1475
15. S. Zeuzem, T. Asselah, and P. Angus Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection Gastroenterology 141 2011 2047 2055
16. A.S. Lok, D.F. Gardiner, E. Lawitz, C. Martorell, G.T. Everson, and R. Ghalib Preliminary study of two antiviral agents for hepatitis C genotype 1 N Engl J Med 3 2012 216 224
17. K. Chayama, S. Takahashi, and J. Toyota Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders Hepatology 55 3 2012 742 748
18. T. Asselah A revolution in HCV treatment with direct-acting antivirals: from non-response to eradication J Hepatol 57 2 2012 455 457